Colorectal Cancer Awareness Month: Navigating the Costs of Treatment
March is National Colorectal Cancer Awareness Month, a crucial time to focus on prevention, early detection, and access to care. Colorectal cancer remains a significant public health challenge, currently ranking as the second leading cause of cancer-related deaths in the United States. Alarmingly, It’s now the leading cause of cancer death for adults under 50, a trend that underscores the need for increased screening and awareness among younger populations. The American Association for Cancer Research estimates that in 2025, over 154,000 people in the U.S. Were diagnosed with colon or rectal cancer, with approximately 52,900 fatalities.
Beyond the emotional and physical toll, a significant barrier to effective treatment is the financial burden. The medications used to combat colorectal cancer, particularly newer targeted therapies and immunotherapies, can be prohibitively expensive. This March, organizations like NeedyMeds are highlighting resources available to aid patients and caregivers manage these costs, ensuring that financial constraints don’t impede access to life-saving treatment. Understanding available assistance programs is a vital step for anyone facing a colorectal cancer diagnosis.
Early detection through screening, such as colonoscopy, remains the most effective way to prevent colorectal cancer. According to the National Cancer Institute, the five-year relative survival rate for localized colorectal cancer is 91.5%, but this rate drops significantly as the cancer spreads. This highlights the importance of regular screenings, especially for individuals over 45, or earlier if there is a family history of the disease.
Chemotherapy: A Cornerstone of Treatment
Chemotherapy remains a foundational element in most colorectal cancer treatment plans, often administered in combination regimens. Established protocols like FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and FOLFIRI (folinic acid, fluorouracil, and irinotecan) have been used for decades and continue to be central to care at all stages of the disease. These regimens are often tailored to the individual patient’s cancer stage, overall health, and genetic profile.
Several chemotherapy drugs are commonly used, including:
- Xeloda (capecitabine): An oral chemotherapy tablet converted to fluorouracil in the body, widely used in colorectal cancer treatment.
- Eloxatin (oxaliplatin): Frequently paired with capecitabine or other agents within the FOLFOX regimen.
- Camptosar (irinotecan): Typically used in the FOLFIRI regimen, often for metastatic disease.
Targeted Therapies: Precision Medicine Approaches
For patients with advanced or metastatic colorectal cancer, targeted therapies are often added to chemotherapy regimens. These therapies focus on specific vulnerabilities within cancer cells, offering a more precise approach to treatment. However, targeted therapies can be among the most expensive oncology drugs available. Tumor biomarker testing is crucial to determine which patients are most likely to benefit from these therapies.
Key targeted therapies include:
- Erbitux (cetuximab): An EGFR (epidermal growth factor receptor) inhibitor administered intravenously, used for advanced colorectal cancer.
- Vectibix (panitumumab): Another EGFR inhibitor specifically for metastatic colorectal cancer with a “wild-type” RAS gene mutation.
Immunotherapy: Harnessing the Power of the Immune System
Immunotherapy has emerged as a powerful treatment option for a subset of patients with advanced colorectal cancer. This approach leverages the body’s own immune system to fight cancer cells. Immunotherapy is particularly effective in patients whose tumors exhibit specific genetic characteristics, namely microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR).
Checkpoint inhibitors, a type of immunotherapy, are commonly used:
- Keytruda (pembrolizumab): Approved as a first-line treatment for eligible colorectal cancer patients with MSI-H or dMMR tumors.
- Opdivo (nivolumab): Another checkpoint inhibitor approved for metastatic colorectal cancer with MSI-H or dMMR.
- Yervoy (ipilimumab): Often used in combination with Opdivo for eligible patients.
Later-Line Treatment Options: Extending Care
When colorectal cancer progresses after initial treatments, several later-line options are available to extend care and improve quality of life. These therapies often target different pathways or mechanisms within the cancer cells.
- Stivarga (regorafenib): An oral targeted therapy for metastatic colorectal cancer that has progressed after other treatments.
- Lonsurf (trifluridine/tipiracil): An oral chemotherapy combination option for metastatic disease following prior therapies.
Financial Assistance Programs: Reducing the Burden
The cost of colorectal cancer treatment can be substantial, encompassing not only medication expenses but too doctor’s visits, hospital stays, and supportive care. Fortunately, numerous organizations offer financial assistance to help patients manage these costs. Beyond medication-specific programs, several organizations provide broader financial support for people living with colorectal cancer.
Diagnosis-Based Assistance Programs are available through organizations like NeedyMeds, which maintains a dedicated list of resources specifically for colorectal cancer patients, including help with copays, treatment costs, and other expenses. NeedyMeds is a non-profit organization dedicated to helping people afford their medications and healthcare costs.
Additional resources can be found through patient advocacy groups and pharmaceutical company patient assistance programs. Exploring these options can significantly alleviate the financial strain associated with colorectal cancer treatment.
Key Takeaways
- Colorectal cancer is increasingly diagnosed in younger adults, making screening even more critical.
- Financial assistance programs are available to help patients afford the high cost of treatment.
- Targeted therapies and immunotherapy offer promising treatment options for advanced disease.
- Early detection through regular screenings remains the most effective way to prevent colorectal cancer.
As Colorectal Cancer Awareness Month continues, it’s vital to prioritize prevention, early detection, and access to affordable treatment. The Colorectal Cancer Alliance is encouraging individuals to “demand innovation” and advocate for progress in the fight against this disease. If you or a loved one is facing a colorectal cancer diagnosis, remember that you are not alone, and resources are available to help navigate the challenges ahead.
The next major event related to colorectal cancer awareness is Dress in Blue Day on Friday, March 6th, a nationwide initiative to raise awareness and honor those affected by the disease. We encourage our readers to share their stories and support colorectal cancer research and advocacy efforts. Please share this article with your network and depart a comment below with your thoughts and experiences.
Related reading